Skip to main content

Table 2 The etiology of AKI in regions

From: Acute kidney injury in Turkey: epidemiological characteristics, etiology, clinical course, and prognosis

 

Marmara-1

Marmara-2

Central Anatolia

Southern Anatolia

Eastern Anatolia

Total

P

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Prerenal

164 (65.3)

99 (93.4)

53 (63.9)

170 (74.2)

64 (59.8)

550 (70.9)

p < 0.001

 Dehydration

104 (41.4)

78 (73.6)

42 (50.6)

83 (36.2)

33 (30.8)

340 (43.8)

 

 Heart failure

32 (12.7)

41 (38.7)

8 (9.6)

52 (22.7)

21 (19.6)

154 (19.8)

 

 Burn

1 (0.4)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (0.1)

 

 Gastrointestinal loss

31 (12.4)

17 (16.0)

23 (27.7)

37 (16.2)

13 (12.1)

121 (15.6)

 

 Liver cirrhosis and ascites

8 (3.2)

2 (1.9)

1 (1.2)

4 (1.7)

2 (1.9)

17 (2.2)

 

 Sepsis

39 (15.5)

6 (5.7)

10 (12.0)

76 (33.2)

17 (15.9)

148 (19.1)

 

Renal

112 (44.6)

74 (69.8)

44 (53.0)

165 (72.1)

62 (57.9)

457 (58.9)

p < 0.001

 Ischemia

19 (7.6)

41 (38.7)

9 (10.8)

29 (12.7)

21 (19.6)

119 (15.3)

 

 Nephrotoxic agent

66 (26.3)

28 (26.4)

25 (30.1)

102 (44.5)

32 (29.9)

253 (32.6)

 

 Aminoglycoside

2 (0.8)

3 (2.8)

1 (1.2)

2 (0.9)

2 (1.9)

10 (1.3)

 

 Colistin

1 (0.4)

2 (1.9)

0 (0.0)

2 (0.9)

3 (2.8)

8 (1.0)

 

 Radiocontrast material

28 (11.2)

3 (2.8)

3 (3.6)

19 (8.3)

9 (8.4)

62 (8.0)

 

 NSAIDs

15 (6.0)

12 (11.3)

5 (6.0)

48 (21.0)

12 (11.2)

92 (11.9)

 

 RAS blocker

8 (3.2)

1 (0.9)

12 (14.5)

52 (22.7)

6 (5.6)

79 (10.2)

 

 Chemotherapeutic drugs

7 (2.8)

7 (6.6)

3 (3.6)

0 (0.0)

1 (0.9)

18 (2.3)

 

 Others

12 (4.8)

9 (8.5)

14 (16.9)

35 (15.3)

6 (5.6)

76 (9.8)

 

 Glomerulonephritis

12 (4.8)

8 (7.5)

4 (4.8)

15 (6.6)

0 (0.0)

39 (5.0)

 

 Vasculitis

5 (2.0)

0 (0.0)

7 (8.4)

5 (2.2)

0 (0.0)

17 (2.2)

 

 Diabetes mellitus

21 (8.4)

14 (13.2)

1 (1.2)

63 (27.5)

5 (4.7)

104 (13.4)

 

 Tubulointerstitial nephritis

9 (3.6)

6 (5.7)

8 (9.6)

5 (2.2)

7 (6.5)

35 (4.5)

 

Postrenal

41 (16.3)

16 (15.1)

15 (18.1)

19 (8.3)

14 (13.1)

105 (13.5)

p = 0.068

 Stone disease

12 (4.8)

2 (1.9)

4 (4.8)

1 (0.4)

4 (3.7)

23 (3.0)

 

 Malignancy

14 (5.6)

7 (6.6)

6 (7.2)

8 (3.5)

6 (5.6)

41 (5.3)

 

 Vesicoureteral reflux

1 (0.4)

0 (0.0)

1 (1.2)

1 (0.4)

1 (0.9)

4 (0.5)

 

 Prostatic disease

16 (6.4)

9 (8.5)

4 (4.8)

9 (3.9)

3 (2.8)

41 (5.3)

 

 Retroperitoneal fibrosis

0 (0.0)

0 (0.0)

1 (1.2)

0 (0.0)

1 (0.9)

2 (0.3)

 
  1. RAS Renin-angiotensin-aldosteron system blocker